Press Releases
Date picker
Category
Results per page
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study
In connection with the interim report for the fourth quarter 2023, Kancera AB (publ) today provides a general operational update and reports that the company has signed a license agreement…
Kancera presents the statistical analysis of top line data from the FRACTAL study
Kancera AB (Kancera) has previously reported the initial top line results from the FRACTAL study and today Kancera presents the statistical analyses that confirm that: the primary objective was met,…
Kancera reports positive top line results from the FRACTAL study
Regulatory
Kancera AB (publ) today reports the top line results from the FRACTAL study, a double-blinded placebo-controlled, explorative phase IIa study of Kancera’s fractalkine blocker KAND567 in high-risk ST-elevation myocardial infarction…
Kancera provides operational update in connection with release of financial interim report for third quarter 2023
In connection with the release of the financial interim report for the third quarter of 2023, Kancera AB (publ) provides an operational update regarding its fractalkine blockers KAN567 and KAND145,…
Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851
Regulatory
The period in brief – financial summary for the third quarterNet sales amounted to SEK 0 million (SEK 0).R&D expenses amounted to SEK 9,2 million (SEK 8,7 million).Operating income for…
Kancera reports that the phase I study of KAND145 has received regulatory approval
Kancera AB (publ) today reports that the Finnish regulatory agency (FIMEA) has approved Kancera’s application to conduct a phase I study of KAND145, the company’s second generation fractalkine blocking candidate…
Kancera announces that the FRACTAL top line results are expected to be presented by the end of December 2023
Regulatory
Kancera AB (publ) today announces that the top line results from the FRACTAL study are delayed. The company expects that results will be presented by the end of December 2023.
Kancera appoints new Chief Medical Officer
Kancera AB (publ) announces that Dr. Markus Jerling has been appointed as new Chief Medical Officer, effective from September 1, 2023.
Kancera provides operational update in connection with release of financial interim report for second quarter
Regulatory
In connection with the release of the financial interim report for the second quarter of 2023, Kancera AB (publ) provides an operational update and announces that top line results from…
Interim Report Second Quarter April 1 – June 30 2023 Kancera AB (publ.), org.no. 556806-8851
Regulatory
The period in brief – financial summary for the second quarter Net sales amounted to SEK 0 million (SEK 0).R&D expenses amounted to SEK 16.5 million (SEK 14.7 million).Operating income…